NCT05350410

Brief Summary

A Pilot Study for the Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program (HALT-AD). This initial four-months pilot study will focus on at least three educational courses (introduction to dementia and lifestyle risk factors, sleep and diet). It may also include a fourth educational course on social connectivity and loneliness. Completion of this initial pilot study will allow for a round of improvements informed by data from the program, on usability, as well as feedback from participants and citizen advisors. This will allow for an iterative process to build the program to its full content, with feedback to optimize the user experience and ensure the accessibility of the content. The information generated from this study will help inform the development of the second program's prototype, expected to benefit from the initial pilot to become more user-friendly, effective and accessible to the target audience. This pilot study will be a longitudinal study of an inception cohort exposed to the HALT-AD online educational program for a four-month study. It will utilize pre- and post- intervention collection of quantitative and qualitative data to evaluate the program's first prototype.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 5, 2022

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

April 6, 2022

Completed
22 days until next milestone

First Posted

Study publicly available on registry

April 28, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 24, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 24, 2022

Completed
2 years until next milestone

Results Posted

Study results publicly available

August 15, 2024

Completed
Last Updated

August 15, 2024

Status Verified

July 1, 2023

Enrollment Period

5 months

First QC Date

April 6, 2022

Results QC Date

July 27, 2023

Last Update Submit

March 14, 2024

Conditions

Keywords

dementiapreventioneducationlifestyle modificationdigital health

Outcome Measures

Primary Outcomes (2)

  • Users' Engagement With the HALT-AD Online Platform by Measuring the Total Amount of Time (in Minutes) Spent Per User on All Courses Combined

    User engagement with the HALT-AD online platform by measuring the average total amount of time (in minutes) spent per user on all courses combined

    4 months

  • Users' Engagement With the HALT-AD Online Platform by Measuring the Percentage of Participants Who Completed All Courses.

    Users' engagement with the HALT-AD online platform by measuring the percentage of participants who completed all courses.

    4 months

Secondary Outcomes (3)

  • Change From Baseline in Knowledge on the HALT-AD Knowledge Assessment Survey at 4 Months

    at baseline and 4 months

  • Change From Baseline in Self-efficacy on the New General Self-Efficacy Scale (NGSE) at 4 Months.

    at baseline and 4 months

  • Change From Baseline in Lifestyle Risk on the HALT-AD Lifestyle Risk Assessment Survey at 4 Months

    at baseline and 4 months

Other Outcomes (5)

  • Acceptability Survey- Users' Acceptability of the HALT-AD Program Content

    completed at 4 months

  • FOCUS Group Discussion- Qualitative Evaluation of the HALT-AD Program Content

    4 months

  • Users' Satisfaction With the Facilitated Support Discussion Groups

    4 months

  • +2 more other outcomes

Study Arms (1)

HALT-AD

EXPERIMENTAL

HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.

Behavioral: HALT-AD

Interventions

HALT-ADBEHAVIORAL

HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.

HALT-AD

Eligibility Criteria

Age50 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent must be obtained and documented (from the participant).
  • Sufficient proficiency in English or Spanish to undergo clinical assessment and participate in an online educational program.
  • Ages 50-85
  • Montreal Cognitive Assessment-Telephone/Blind Version (T-MoCA) score ≥18/22
  • Technical ability to participate in an online educational program (i.e. ability to operate a computer/tablet and gain internet access; ability to send and receive emails)
  • Sufficient vision and hearing to participate in online educational program (judgement of site investigator)
  • Ability to sit comfortably for a period of at least 30 minutes

You may not qualify if:

  • Participants who, in the opinion of the co-PIs, are not able to complete trial procedures or adhere to the schedule of study assessments will be excluded from study participation.
  • Individuals where English or Spanish is not sufficiently proficient for clinical assessment, and participation in a web-based educational program.
  • Participants who do not have sufficient vision and hearing to participate in an online educational program
  • Individuals who do not have the technical ability to participate in an online educational program. Technical ability is defined as ability to operate a computer/tablet and gain internet access; ability to send and receive emails)
  • Total Score on the T-MoCA \<18
  • Individuals who have an advanced degree (e.g. Master's, MD, PhD) in an area related to brain health will not be eligible to participate.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Alzheimer's Disease Cooperative Study (ADCS)

La Jolla, California, 92037, United States

Location

Related Publications (14)

  • Ostergren JE, Heeringa SG, Leon CFM, Connell CM, Roberts JS. The Influence of Psychosocial and Cognitive Factors on Perceived Threat of Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2017 Aug;32(5):289-299. doi: 10.1177/1533317517714552. Epub 2017 Jun 13.

    PMID: 28605999BACKGROUND
  • 2020 Alzheimer's disease facts and figures. Alzheimers Dement. 2020 Mar 10. doi: 10.1002/alz.12068. Online ahead of print.

    PMID: 32157811BACKGROUND
  • Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013 Apr 4;368(14):1326-34. doi: 10.1056/NEJMsa1204629.

    PMID: 23550670BACKGROUND
  • Agency, C.o.S.D.H.a.H.S., The Alzheimer's Project Clinical Rountable. Alzheimer's disease and related dementias in San Diego county. 2018.

    BACKGROUND
  • Living, A.f.C., Profile of Older Americans. 2019.

    BACKGROUND
  • Network, U.E.R.R.I.o.A.L.s., Latinos and Alzheimer's Disease: New Numbers Behind the Crisis. 2016.

    BACKGROUND
  • Velasco-Mondragon E, Jimenez A, Palladino-Davis AG, Davis D, Escamilla-Cejudo JA. Hispanic health in the USA: a scoping review of the literature. Public Health Rev. 2016 Dec 7;37:31. doi: 10.1186/s40985-016-0043-2. eCollection 2016.

    PMID: 29450072BACKGROUND
  • Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y). 2018 May 3;4:195-214. doi: 10.1016/j.trci.2018.03.009. eCollection 2018.

    PMID: 29955663BACKGROUND
  • Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbaek G, Teri L, Mukadam N. Dementia prevention, intervention, and care. Lancet. 2017 Dec 16;390(10113):2673-2734. doi: 10.1016/S0140-6736(17)31363-6. Epub 2017 Jul 20. No abstract available.

    PMID: 28735855BACKGROUND
  • Kivipelto M, Solomon A, Ahtiluoto S, Ngandu T, Lehtisalo J, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Nissinen A, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimers Dement. 2013 Nov;9(6):657-65. doi: 10.1016/j.jalz.2012.09.012. Epub 2013 Jan 17.

    PMID: 23332672BACKGROUND
  • Cummings J, Reiber C, Kumar P. The price of progress: Funding and financing Alzheimer's disease drug development. Alzheimers Dement (N Y). 2018 Jun 13;4:330-343. doi: 10.1016/j.trci.2018.04.008. eCollection 2018.

    PMID: 30175227BACKGROUND
  • Pendlebury ST, Welch SJ, Cuthbertson FC, Mariz J, Mehta Z, Rothwell PM. Telephone assessment of cognition after transient ischemic attack and stroke: modified telephone interview of cognitive status and telephone Montreal Cognitive Assessment versus face-to-face Montreal Cognitive Assessment and neuropsychological battery. Stroke. 2013 Jan;44(1):227-9. doi: 10.1161/STROKEAHA.112.673384. Epub 2012 Nov 8.

    PMID: 23138443BACKGROUND
  • Chen, G., S.M. Gully, and D. Eden, Validation of a new general self-efficacy scale. Organizational research methods, 2001. 4(1): p. 62-83.

    BACKGROUND
  • Metlife Foundation. What America Thinks - Metlife Foundation Alzheimer's Survey. Available at: https://www.metlife.com/content/dam/microsites/about/corporateprofile/ alzheimers-2011.pdf. 2011.

    BACKGROUND

MeSH Terms

Conditions

DementiaAlzheimer Disease

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersTauopathiesNeurodegenerative Diseases

Results Point of Contact

Title
Sara Moukarzel, PhD, Program Manager
Organization
Alzheimer's Disease Cooperative Study

Study Officials

  • Howard Feldman, MDCM FRCP(C)

    Alzheimer's Disease Cooperative Study (ADCS)

    STUDY DIRECTOR
  • Sarah Banks, PhD, ABPP-CN

    Alzheimer's Disease Cooperative Study (ADCS)

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: This pilot study will be a longitudinal study of an inception cohort exposed to the HALT AD online educational program for a four month study. It will utilize pre- and post- intervention collection of quantitative and qualitative data to evaluate the program's first prototype. Cognitively normal midlife and older-adult participants will be eligible to participate in this pilot study with the following inclusion criteria: * Ages 50-85 * Montreal Cognitive Assessment-Telephone/Blind version (T-MoCA) Score equal to or greater than 18/22 * Sufficient proficiency in English or Spanish to undergo clinical assessment and participate * Technical ability to participate * Sufficient vision and hearing to participate 20 participants will be enrolled at UCSD * 10 will complete the English version * 10 will complete the Spanish version Aim to recruit 50% women and enroll a diverse participant sample across varied age ranges within both language groups
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 6, 2022

First Posted

April 28, 2022

Study Start

April 5, 2022

Primary Completion

August 24, 2022

Study Completion

August 24, 2022

Last Updated

August 15, 2024

Results First Posted

August 15, 2024

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations